Prochlorperazine Suppositories Rx
Generic Name and Formulations:
Various generic manufacturers
Indications for Prochlorperazine Suppositories:
Severe nausea and vomiting.
Oral: 5–10mg 3–4 times daily; usual max 40mg/day. Rectal: 25mg twice daily.
<2yrs or <20lbs: not recommended. Oral: 20–29lbs: 2½mg once or twice daily; max 7.5mg/day. 30–39lbs: 2½mg 2–3 times daily; max 10mg/day. 40–85lbs: 2½mg 3 times daily or 5mg twice daily; max 15mg/day.
Coma. CNS depression. Pediatric surgery. Children <2yrs or <20lbs.
Discontinue 48 hrs before to 24 hrs after myelography. Cardiovascular disease. Epilepsy. Bone marrow depression. Reye's syndrome. Glaucoma. History of breast cancer. Exposure to extreme heat. Monitor blood, liver, and ocular function. Write ℞ using fractions rather than decimals. Children with acute illness or dehydration. Debilitated. Elderly. Pregnancy, nursing mothers: not recommended.
Potentiates CNS depression with alcohol, other CNS depressants. Potentiates α-blockers. Levels of both drugs increased with propranolol. May potentiate phenytoin; monitor for toxicity. Adjust anticonvulsant doses. May antagonize oral anticoagulants. Hypotension potentiated with thiazide diuretics. Antagonized by anticholinergics. Decreases guanethidine effects. Monitor for neurologic toxicity with lithium; discontinue if occurs. May cause false (+) PKU test.
Drowsiness, dizziness, amenorrhea, blurred vision, other anticholinergic effects, skin reactions, hypotension, cholestatic jaundice, photosensitivity, leukopenia, agranulocytosis, neuroleptic malignant syndrome, agitation, insomnia, dystonias, extrapyramidal reactions, pseudoparkinsonism, tardive dyskinesia, may mask emetic signs of disease, lowered seizure threshold, EKG changes, aspiration, deep sleep, hyperprolactinemia, paradoxical excitement in children.
Formerly known under the brand name Compazine.
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Prioritizing Rest in Hospital Settings: Poor Sleep Increases Costs, Complications, and Mortality
- Pain Catastrophizing Decreases in Rheumatoid Arthritis After DMARD Initiation
- Addressing Commercial Incentives in the Medical Device Industry
- Cancer Patients Treated With Step III Opioids Often Have Sleep Disturbances
- Low Literacy Self-Management Program for Chronic Pain May Be Effective